IBEX 35
10.943,70 -7,80 (-0,07%) Euro Stoxx 50
4.894,02 -8,58 (-0,18%) Dólar/Euro
1,0716 +0,0007 (+0,06%) Petróleo Brent
86,48 +0,09 (+0,10%) Oro
2.336,90 +0,30 (+0,01%) Bitcoin EUR
56.203,14 -1.111,14 (-1,94%)
Vicapsys Life Sciences, Inc. (VICP)
Vicapsys Life Sciences, Inc.
7778 Mcginnis Ferry Road
Suite 270
Suwanee, GA 30024
United States
972 891 8033
https://vicapsys.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 2
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Federico Pier | CEO, Executive Chairman & Interim President | 120k | N/A | 1968 |
| Mr. Jeffery Wright CPA, CPA | Chief Financial Officer | 90k | N/A | 1983 |
| Dr. Mark C. Poznansky M.D., Ph.D. | Chief Scientist Advisor & Founder | N/A | N/A | N/A |
Descripción
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.
Gobierno corporativo
El ISS Governance QualityScore de Vicapsys Life Sciences, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
